Association of MTHFR, GSTP1, ERCC1 polymorphisms and response to FOLFOX in colorectal cancer patients
SHEN Dong-ya, XIE Hai-tang, CHEN Yao, XIAO Jian, ZHANG Wei, ZHANG Xue, ZHOU Hong-hao
2015, 20(1):
75-81.
Asbtract
(
210 )
PDF (722KB)
(
265
)
References |
Related Articles |
Metrics
AIM: To investigate the relationship between the polymorphisms of MTHFR, GSTP1,ERCC1 and the response to FOLFOX chemotherapy in advanced colorectal cancer. METHODS: A total of 150 patients diagnosed as an advanced colorectal cancer by the pathology were treated with FOLFOX chemotherapy and DNA of peripheral blood-leukocytes was obtained before the treatment, MTHFR,GSTP1,ERCC1 genetype were detected by the HRM-SNP method. RESULTS: (1)The frequencies of MTHFR429 Glu/Glu, Glu/Ala, Ala/Ala were 59.1%, 37.0%, 3.9%; MTHFR 222 Ala/Ala, Ala/Val, Val/Val were 12.6%,47.2%,40.1%;GSTP1-105 Ile/Ile, Ile/Val,Val/Val genetypes were 63.0%,33.1%,3.9%;ERCC1-118AA, AT,TT genetypes were 50.4%, 41.7%,7.9%,respectively.(2)The effective rate of FOLFOX chemotherapy among patients with GSTP1-105 Ile/Ile,Ile/Val+Val/Val genetypes were 19.7%,20.5%,OR=2.876,95%CI(1.288,6.424),P<0.05;MTHFR 222 Ala/Ala, Ala/Val+Val/Val genetypes were 11.8%,28.3%,OR=2.236, 95%CI(1.020,5.017),P<0.05,respectively,which was a significant difference. CONCLUSION: The polymorphisms of MTHFR,GSTP1,ERCC1 correlates with the clinical response to FOLFOX chemotherapy and the genetype detected by the HRM-SNP method may be a predictor of sensitivity to FOLFOX chemotherapy.